



# Core Project R03OD032624



## Details









| Projects        | Name   | Award        | Publications    | Repositories   | Analytics    |
|-----------------|--|--------------|-----------------|----------------|--------------|
| 1R03OD032624-01 | Using Common Fund datasets for xenobiotic localization | \$304,000.00 | 11 publications | 0 repositories | 0 properties |











## Publications

Published works associated with this project.

| ID  | Title   | Authors                   | R<br>C<br>R | SJ<br>R | Cita<br>tion<br>s | Cit./<br>yea<br>r | Journal              | Publ<br>ishe<br>d | Upda<br>ted        |
|---|---|---------------------------|-------------|---------|-------------------|-------------------|----------------------|-------------------|--------------------|
| <a href="#">36116580</a><br><a href="#">DOI</a> | Mucoadhesive carriers for oral drug delivery. | Raj Kumar<br>...1 more... | 5.<br>2     | 0       | 24                | 12                | J Control<br>Release | 2022              | Dec<br>29,<br>2024 |

|   |   |  |      |       |    |    |                       |      |                           |              |
|---|---|--|------|-------|----|----|-----------------------|------|---------------------------|--------------|
|   |   | Md Nurunnabi   |      |       |    |    |                       |      |                           | (1 week ago) |
| <a href="#">37238639</a> <br><a href="#">DOI</a>      | $\beta$ -Glucan and Fatty Acid Based Mucoadhesive Carrier for Gastrointestinal Tract Specific Local and ... | Stephanie Vargas Esquivel ...5 more...<br>Md Nurunnabi | 4.46 | 1.179 | 7  | 7  | Biomolecules          | 2023 | Dec 29, 2024 (1 week ago) |              |
| <a href="#">38104896</a> <br><a href="#">DOI</a>      | Potentials of ionic liquids to overcome physical and biological barriers.                                   | Elfa Beaven ...7 more...<br>Md Nurunnabi               | 3.82 | 0     | 5  | 5  | Adv Drug Deliv Rev    | 2024 | Dec 28, 2024 (1 week ago) |              |
| <a href="#">36971908</a> <br><a href="#">DOI</a>  | Oral delivery of RNAi for cancer therapy.   | Humayra Afrin ...4 more...<br>Md Nurunnabi             | 3.06 | 0     | 11 | 11 | Cancer Metastasis Rev | 2023 | Dec 28, 2024 (1 week ago) |              |
| <a href="#">38065244</a> <br><a href="#">DOI</a>  | Emerging delivery approaches for targeted pulmonary fibrosis treatment.                                     | Rimpy Diwan ...2 more...<br>Md Nurunnabi               | 3.05 | 0     | 5  | 5  | Adv Drug Deliv Rev    | 2024 | Dec 28, 2024 (1           |              |


|   |   |  |      |   |    |     |                           |      |                           |           |
|---|---|--|------|---|----|-----|---------------------------|------|---------------------------|-----------|
|   |   |  |      |   |    |     |                           |      |                           | week ago) |
| <a href="#">37350332</a> <br><a href="#">DOI</a>      | $\beta$ -Glucan-Mediated Oral Codelivery of 5FU and Bcl2 siRNA Attenuates Stomach Cancer. | Humayra Afrin<br>...6 more...<br>Md Nurunnabi    | 1.63 | 0 | 3  | 3   | ACS Appl Mater Interfaces | 2023 | Dec 29, 2024 (1 week ago) |           |
| <a href="#">36445310</a> <br><a href="#">DOI</a>      | Myofibroblast specific targeting approaches to improve fibrosis treatment.                | Elfa Beaven<br>...3 more...<br>Md Nurunnabi      | 1.62 | 0 | 11 | 5.5 | Chem Commun (Camb)        | 2022 | Dec 29, 2024 (1 week ago) |           |
| <a href="#">37562554</a> <br><a href="#">DOI</a>  | A photothermal driven chemotherapy for the treatment of metastatic melanoma.              | Himanshu N Bhatt<br>...6 more...<br>Md Nurunnabi | 0.8  | 0 | 3  | 3   | J Control Release         | 2023 | Dec 29, 2024 (1 week ago) |           |
| <a href="#">36753355</a> <br><a href="#">DOI</a>  | Potential and Progress of 2D Materials in Photomedicine for Cancer Treatment.             | Himanshu N Bhatt<br>...5 more...<br>Md Nurunnabi | 0.79 | 0 | 2  | 2   | ACS Appl Bio Mater        | 2023 | Dec 28, 2024 (1 week ago) |           |


|  |   |   |   |   |   |   |                       |      |                           |
|--|---|---|---|---|---|---|-----------------------|------|---------------------------|
| <a href="#">38446352</a> <a href="#">DOI</a> <a href="#">↗</a> | Liver fibrosis pathologies and potentials of RNA based therapeutics modalities. | Rimpy Diwan<br>...3 more...<br>Md Nurunnabi | 0 | 0 | 0 | 0 | Drug Deliv Transl Res | 2024 | Dec 28, 2024 (1 week ago) |
| <a href="#">37554053</a> <a href="#">DOI</a> <a href="#">↗</a> | Carbon Coated Iron-Cobalt Nanoparticles for Magnetic Particle Imaging.          | Raj Kumar<br>...5 more...<br>Md Nurunnabi   | 0 | 0 | 0 | 0 | ACS Appl Bio Mater    | 2023 | Dec 29, 2024 (1 week ago) |

Notes

RCR [Relative Citation Ratio](#) [↗](#)

SJR [Scimago Journal Rank](#) [↗](#)





| Name    | Tags | Last Commit | Avg Issue | Avg PR | Languages | License | Readme | Contributing | Dependencies |
|---------|------|-------------|-----------|--------|-----------|---------|--------|--------------|--------------|
| No data |      |             |           |        |           |         |        |              |              |

## Notes

**Repository** For storing, tracking changes to, and collaborating on a piece of software.

**PR** "Pull request", a draft change (new feature, bug fix, etc.) to a repo.

**Closed/Open** Resolved/unresolved.

**Avg Issue/PR** Average time issues/pull requests stay open for before being closed.

Only the `main` /default branch is considered for metrics like # of commits.

# of dependencies is totaled from all manifests in repo, direct and transitive, e.g. `package.json` + `package-lock.json`.

## Notes

Active Users      [Distinct users who visited the website](#) .

New Users      [Users who visited the website for the first time](#) .

Engaged Sessions      [Visits that had significant interaction](#) .

"Top" metrics are measured by number of engaged sessions.